CD36 and acute myeloid leukemia: CD36+ LSC were shown to be chemoresistant consistent with the findings by Farge et al. on increased FAO, up-regulated CD36 and an OXPHOS signature in pre-existing, residual AML cells that survive cytarabine treatment in a cohort of patient derived xenografts (228).